Nyenta.com

Menu
  • Home
  • Business
  • Books
  • Entertainment
  • Financial
  • Music
  • Banking
  • Health
  • Technology
Menu

BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options
Nyenta.com/10226802

Trending...
  • SVB DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In SVB To Contact Him Directly To Discuss Their Options
  • The Magic School Bus: Lost In The Solar System Live At Tribeca PAC
  • COINBASE INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Coinbase To Contact Him Directly To Discuss Their Options
NEW YORK, Jan. 28, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BVS.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Bioventus is a medical device company that focuses on developing and commercializing clinical treatments to engage and enhance the body's natural healing process.

On January 20, 2021, Bioventus filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") in connection with the IPO, which, after several amendments, was declared effective by the SEC on February 10, 2021 (the "Registration Statement").

On or about February 11, 2021, pursuant to the Registration Statement, Bioventus conducted the IPO, issuing 8 million shares of its Class A common stock to the public at the Offering price of $13.00 per share.

On February 12, 2021, Bioventus filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the "Prospectus" and, together with the Registration Statement, the "Offering Documents").

More on Nyenta.com
  • Where to Commission a Custom 1/6 Head Sculpt?
  • Shima Capital's Founder Yida Gao Teaches Crypto Finance Course at MIT
  • Max Amini Announces Powerful Interview with Reza Pahlavi, Former Crown Prince of Iran; to Premiere April 1st
  • Trump Bus rolls into Georgia Ron DeSantis event overshadowing Tiny Desantis box truck at Veterans for Trump lead mini-rally
  • Palos Verdes Real Estate Agent Promotes Homes To MORE Opportune Buyers For Significantly MORE Money

The Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (1) Bioventus suffered from significant liquidity issues; (2) the Company's rebate practices were unsustainable; (3) accordingly, Defendants overstated the Company's business and financial prospects; (4) Bioventus maintained deficient disclosure controls and procedures and internal control over financial reporting with respect to the timely recognition of quarterly rebates; (5) all the foregoing increased the risk that the Company would be forced to recognize a significant non-cash impairment charge, could not timely file one or more of its financial reports, would have to amend one or more of its financial statements, and could not meet its financial obligations as they came due; and (6) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

On November 16, 2022, Bioventus issued a press release announcing that it could not timely file its quarterly report for third quarter of 2022 because "of the recent decline in the Company's market capitalization subsequent to its previously announced financial results for the third quarter of 2022," which resulted in the Company needing "additional time . . . to assess whether a non-cash impairment charge is required for the third quarter of 2022." Bioventus also revealed that it "is seeking resolution related to the validity of a revised invoice" for certain "rebate claims" and that "[t]he recognition of additional rebates may impact Bioventus' recently announced revenue guidance." In addition, Bioventus disclosed that "its internal controls related to the timely recognition of quarterly rebates were inadequate specifically for the period ended October 1, 2022" and that the Company "is also evaluating whether [it] will be able to meet all of its financial obligations as they come due within one year after the date its financial statements for the period ended October 1, 2022, are issued."

More on Nyenta.com
  • Moore Kuehn Encourages DFFN, KMF, CSTI, and BGRY Investors to Contact Law Firm
  • Access Control Systems Expands and Rebrands as Guardian Access Solutions as Part of Increased Service Offerings
  • Peachtree Immediate Care Opens Urgent Care Clinic in Marietta
  • Olga Torres Named Top Advisor by Foreign Investment Watch
  • Attorney Steve Hilst Named Partner at Bisnar Chase

On this news, Bioventus's stock price fell $1.00 per share, or 33.67%, to close at $1.97 per share on November 17, 2022.

Then, on November 21, 2022, Bioventus issued a press release announcing revised third quarter 2022 results to account for "additional rebate claims related to certain of the Company's products and a non-cash impairment charge" that amounted to $189.2 million "due to the recent decline in our market capitalization subsequent to our previously announced financial results for the three and nine months ended October 1, 2022." That same day, Bioventus belatedly filed its quarterly report on Form 10-Q with the SEC for the third quarter of 2022, advising of various changes to Bioventus's historical practices that were necessary to account for rebates, stating that these changes materially impacted the Company's evaluation of its ability to meet debt covenants, resulting in liquidity and going concern disclosures.

On this news, Bioventus's stock price fell $0.07 per share, or 3.72%, to close at $1.81 per share on November 22, 2022, representing a total decline of 86.08% from the IPO price.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Bioventus's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Nyenta.com
  • Sherry Orel Joins STS Capital Partners
  • American Equus Expands Product Line with Suomy Riding Helmets
  • Lewy Body Dementia Resource Center Introduces a New Video Production
  • Arbutus Medical Launches TrakPak® with QuikBow™ to Improve Skeletal Traction, Announces Successful Cases
  • Waterleaf International, LLC Announces Hiring of Chief Sales Officer
  • Experimental Detachment: Why Avant-Garde Fashion Is Starting to Feel Tone-Deaf
  • EVERWILD Returns To Legend Valley With Lineup Featuring Pepper, Bone Thugs-N-Harmony, and host band Tropidelic
  • World's First AI-Generated Satirical News Website Launches, Outperforms Humans in Humor and Intelligence
  • Kookalimba Launches KooKalimba 17 keys Acrylic Kalimba
  • Fab Figures releases 1:6th Scale Female Long Sleeve Faux Leather Jackets
  • SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm
  • Striction BP [[Update Mar2023!]]- Is It Safe? Must Read This
  • Genie Script: 20 Word Script by Wesley Virgin
  • BMI WINS MASSIVE VICTORY FOR SONGWRITERS, COMPOSERS & PUBLISHERS FOR LIVE CONCERT RATES
  • Sky Harbour Group Corporation Announces its 2022 Financial Results, Modification of SH Capital's 2021 Project Portfolio, Recapitalization of its Obligated Group, and Opening of its Campus at Miami-Opa Locka Executive Airport
  • Jake Paul Teams Up with The Berman Team, Sponsored by Berman Law Group for charity event supporting Boxing Bullies
  • Matt Fogelgren to Join Cleartelligence Executive Team as Chief Revenue Officer
  • ACI's Forum on FinTech & Emerging Payment Systems is back to New York City!
  • Keebos Unveils Keebos 2.0: The Ultimate Crossbody Phone Case
  • Kookalimba Launches K80M Loving Heart Mini Kalimba, the Perfect Musical Companion

Popular on Nyenta

  • New Rochelle: 2023 State of the City Address
  • New Rochelle: Registration Begins March 6 for Summer Day Camps
  • New Rochelle: Upcoming March events
  • New Rochelle: Registration Now Open for Girls on the Run
  • New Rochelle: City Launches New Special Needs Summer Employment Program
  • New Book - A Little Boy on Ramree Island By Aung Z. and Jill Mong
  • New Rochelle: Upcoming March events
  • Yonkers Mayor Spano & Yonkers Police Department Unveil Initiative to Combat Shoplifting at Local Retail Stores
  • Yonkers Police arrest three NYC men for property crimes; 17 suspected stolen catalytic converters discovered
  • New Rochelle: Armed Robbery – Liquor Store 558 North Ave

Similar on Nyenta

  • Top Causes of Car Accidents in NYC
  • Shima Capital's Founder Yida Gao Teaches Crypto Finance Course at MIT
  • Moore Kuehn Encourages DFFN, KMF, CSTI, and BGRY Investors to Contact Law Firm
  • Olga Torres Named Top Advisor by Foreign Investment Watch
  • ASI Hosts 2023 Executive Summit for Partners and Announces Annual Award Winners
  • Namify's Website Name Generator: The Ultimate Solution for Finding Your Perfect Website Name
  • New Report Reveals What Teen Girls Think About TikTok, Instagram, and the Impact That Social Media Has on Their Lives
  • TAL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against TAL Education Group and Encourages Investors to Contact the Firm
  • Sherry Orel Joins STS Capital Partners
  • SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm
Copyright © 2023 nyenta.com | Terms of Service | Privacy Policy | Contribute | Contact Us